Article

Dysregulation of the Norepinephrine Transporter Sustains Cortical Hypodopaminergia and Schizophrenia-Like Behaviors in Neuronal Rictor Null Mice

Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
PLoS Biology (Impact Factor: 11.77). 06/2010; 8(6):e1000393. DOI: 10.1371/journal.pbio.1000393
Source: PubMed

ABSTRACT The mammalian target of rapamycin (mTOR) complex 2 (mTORC2) is a multimeric signaling unit that phosphorylates protein kinase B/Akt following hormonal and growth factor stimulation. Defective Akt phosphorylation at the mTORC2-catalyzed Ser473 site has been linked to schizophrenia. While human imaging and animal studies implicate a fundamental role for Akt signaling in prefrontal dopaminergic networks, the molecular mechanisms linking Akt phosphorylation to specific schizophrenia-related neurotransmission abnormalities have not yet been described. Importantly, current understanding of schizophrenia suggests that cortical decreases in DA neurotransmission and content, defined here as cortical hypodopaminergia, contribute to both the cognitive deficits and the negative symptoms characteristic of this disorder. We sought to identify a mechanism linking aberrant Akt signaling to these hallmarks of schizophrenia. We used conditional gene targeting in mice to eliminate the mTORC2 regulatory protein rictor in neurons, leading to impairments in neuronal Akt Ser473 phosphorylation. Rictor-null (KO) mice exhibit prepulse inhibition (PPI) deficits, a schizophrenia-associated behavior. In addition, they show reduced prefrontal dopamine (DA) content, elevated cortical norepinephrine (NE), unaltered cortical serotonin (5-HT), and enhanced expression of the NE transporter (NET). In the cortex, NET takes up both extracellular NE and DA. Thus, we propose that amplified NET function in rictor KO mice enhances accumulation of both NE and DA within the noradrenergic neuron. This phenomenon leads to conversion of DA to NE and ultimately supports both increased NE tissue content as well as a decrease in DA. In support of this hypothesis, NET blockade in rictor KO mice reversed cortical deficits in DA content and PPI, suggesting that dysregulation of DA homeostasis is driven by alteration in NET expression, which we show is ultimately influenced by Akt phosphorylation status. These data illuminate a molecular link, Akt regulation of NET, between the recognized association of Akt signaling deficits in schizophrenia with a specific mechanism for cortical hypodopaminergia and hypofunction. Additionally, our findings identify Akt as a novel modulator of monoamine homeostasis in the cortex.

Full-text

Available from: Gregg D Stanwood, Jun 08, 2015
0 Followers
 · 
252 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The noradrenergic and p38 mitogen activated protein kinase (p38 MAPK) systems are implicated in cocaine-elicited behaviors. Previously, we demonstrated a role for p38 MAPK-mediated norepinephrine transporter (NET) T30-phosphorylation in cocaine-induced NET upregulation (1). The present study explored the functional interaction between p38 MAPK-mediated NET regulation and cocaine-induced behaviors. In-vitro cocaine treatment of mouse prefrontal cortex (PFC) synaptosomes resulted in enhanced NET function, surface expression and phosphorylation. Pretreatment with PD169316, a p38 MAPK inhibitor completely blocked cocaine-mediated NET upregulation and phosphorylation. In mice, in-vivo administration of p38 MAPK inhibitor SB203580 completely blocked cocaine-induced NET upregulation and p38 MAPK activation in the PFC and nucleus accumbens (NAc). When tested for cocaine-induced locomotor sensitization and conditioned place preference (CPP), mice receiving SB203580 on cocaine challenge day or on post conditioning test day exhibited significantly reduced cocaine sensitization and CPP. TAT-peptide strategy was utilized to test the involvement of NET-T30 motif. In-vitro treatment of synaptosomes with TAT-NET-T30 (wild-type peptide) completely blocked cocaine-mediated NET upregulation and phosphorylation. In-vivo administration of TAT-NET-T30 peptide but not TAT-NET-T30A (mutant peptide) completely blocked cocaine-mediated NET upregulation and phosphorylation. In cocaine CPP paradigm, mice receiving TAT-NET-T30, but not TAT-NET-T30A on post-conditioning test day exhibited significantly reduced cocaine CPP. Following extinction, TAT-NET-T30 when given prior to cocaine challenge, significantly reduced reinstatement of cocaine-CPP. These results demonstrate that the direct inhibition of p38 MAPK or the manipulation of NET-T30 motif/phosphorylation via TAT-peptide strategy prevents cocaine-induced NET upregulation, locomotor sensitization and CPP suggesting a role for T30-linked NET regulation in cocaine-elicited behaviors. Copyright © 2015, The American Society for Biochemistry and Molecular Biology.
    Journal of Biological Chemistry 02/2015; 290(17). DOI:10.1074/jbc.M114.612192 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: mTOR (the mechanistic target of rapamycin) is an atypical serine/threonine kinase involved in regulating major cellular functions including growth and proliferation. Deregulations of the mTOR signaling pathway is one of the most commonly observed pathological alterations in human cancers. To this end, oncogenic activation of the mTOR signaling pathway contributes to cancer cell growth, proliferation and survival, highlighting the potential for targeting the oncogenic mTOR pathway members as an effective anti-cancer strategy. In order to do so, a thorough understanding of the physiological roles of key mTOR signaling pathway components and upstream regulators would guide future targeted therapies. Thus, in this review, we summarize available genetic mouse models for mTORC1 and mTORC2 components, as well as characterized mTOR upstream regulators and downstream targets, and assign a potential oncogenic or tumor suppressive role for each evaluated molecule. Together, our work will not only facilitate the current understanding of mTOR biology and possible future research directions, but more importantly, provide a molecular basis for targeted therapies aiming at key oncogenic members along the mTOR signaling pathway. Copyright © 2014. Published by Elsevier B.V.
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 11/2014; 1846(2):638-654. DOI:10.1016/j.bbcan.2014.10.007 · 7.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanistic target of rapamycin (mTOR) signaling pathway is a crucial cellular signaling hub that, like the nervous system itself, integrates internal and external cues to elicit critical outputs including growth control, protein synthesis, gene expression, and metabolic balance. The importance of mTOR signaling to brain function is underscored by the myriad disorders in which mTOR pathway dysfunction is implicated, such as autism, epilepsy, and neurodegenerative disorders. Pharmacological manipulation of mTOR signaling holds therapeutic promise and has entered clinical trials for several disorders. Here, we review the functions of mTOR signaling in the normal and pathological brain, highlighting ongoing efforts to translate our understanding of cellular physiology into direct medical benefit for neurological disorders.
    Neuron 10/2014; 84(2):275-291. DOI:10.1016/j.neuron.2014.09.034 · 15.98 Impact Factor